Ireland
--:--IST
Priya Life Science Clinical trial register
Trackers› Clinical trials› Matsuyama
Clinical trial register · Japan

Clinical Trials in Matsuyama, 2026

Every study on the ClinicalTrials.gov registry that lists a site in Japan and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 2493 matching records held by the registry are in this view. Synced 22 Oct 2026, 03:19 UTC
2493
Studies in scope
all four open statuses
1263
Recruiting now
open to new participants
349
Lead sponsors
across recruiting studies
Top sites
Chūōku 90 Fukuoka 84 Kashiwa 72 Bunkyō City 61 Kōtoku 56
Narrow the registerReset
Recruitment status
Phase
Site location
Chūōku90 Fukuoka84 Kashiwa72 Bunkyō City61 Kōtoku56
All 186 locations
Target enrolment
to

Trials with a site in Matsuyama

19 of 2493 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Sites in Japan
Start
Recruiting
AstraZeneca
Phase 2
320
Aomori, Bunkyō City, Fukuoka, Hamamatsu, Hitachi-Naka, Iizuka-shi, Kawachinagano-shi, Matsuyama
2025-12-15
Recruiting
AstraZeneca
Phase 3
1,100
Chiba, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Osaka, Suita-shi
2025-12-04
Recruiting
AstraZeneca
Phase 3
420
Akashi, Bunkyō City, Himeji-shi, Kōtoku, Kumamoto, Matsumoto-shi, Matsuyama, Meguro-ku
2025-11-11
Recruiting
AstraZeneca
Phase 3
400
Chūōku, Fukuoka, Hiroshima, Iwakuni-shi, Kashiwa, Kawasaki-shi, Kyoto, Matsuyama
2025-10-31
Recruiting
AstraZeneca
Phase 3
800
Chūōku, Hidaka-shi, Isehara-shi, Kashiwa-shi, Kōtoku, Kurume-shi, Matsuyama, Minatoku
2025-08-01
Recruiting
A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell Malignancies
NCT06564038Chronic Lymphocytic Leukaemia, Small Lymphocytic Lymphoma, Mantle-cell Lymphoma, Large B-cell Lymphoma
AstraZeneca
Phase 1/2
408
Kōtoku, Matsuyama, Nagoya
2025-01-30
Active, closed
AstraZeneca
Phase 3
863
Amagasaki-shi, Hakodate-shi, Hiroshima, Kitaadachi-gun, Kitakyushu-shi, Matsuyama, Nagoya, Nishinomiya-shi
2023-11-09
Active, closed
AstraZeneca
Phase 3
895
Bunkyō City, Fukuoka, Kashiwa, Kawasaki-shi, Kōtoku, Matsuyama, Nagoya, Okayama
2023-10-24
Recruiting
AstraZeneca
Phase 3
800
Fukuoka, Ginowan-shi, Hidaka-shi, Kagoshima, Kōtoku, Kurume-shi, Maebashi, Matsuyama
2023-09-22
Active, closed
AstraZeneca
Phase 3
111
Kanazawa, Kashiwa, Matsuyama, Musashino-shi, Osakasayama-shi, Yokohama
2023-06-27
Active, closed
AstraZeneca
Phase 3
594
Bunkyō City, Chūōku, Kōtoku, Kurashiki-shi, Kurume-shi, Matsuyama, Nagoya, Niigata
2022-09-15
Active, closed
AstraZeneca
Phase 3
454
Chūōku, Fukuoka, Kashiwa, Matsuyama, Niigata, Okayama, Osaka, Sakai
2021-10-28
Active, closed
AstraZeneca
Phase 3
315
Chiba, Chūōku, Hidaka-shi, Hirakata-shi, Kitaadachi-gun, Kōtoku, Kumamoto, Matsuyama
2021-06-30
Active, closed
AstraZeneca
Phase 3
805
Chūōku, Kashiwa-shi, Kōtoku, Kurume-shi, Kyoto, Matsuyama, Minatoku, Nagoya
2020-05-05
Active, closed
AstraZeneca
Phase 2
401
Chūōku, Kanazawa, Kurume-shi,, Matsuyama, Nagoya, Sendai, Sunto-gun, Ube-shi
2018-12-21
Active, closed
AstraZeneca
Phase 3
1,018
Bunkyō City, Fukuoka, Hirosaki-shi, Kanazawa, Kita-gun, Koshigaya-shi, Kōtoku, Matsuyama
2018-05-14
Active, closed
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy
NCT01874353Platinum Sensitive, BRCA Mutated, Relapsed Ovarian Cancer, Following Complete or Partial Response to Platinum Based Chemotherapy
AstraZeneca
Phase 3
327
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Osakasayama-shi, Sapporo
2013-09-03
Active, closed
Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Ovarian Cancer Following First Line Platinum Based Chemotherapy.
NCT01844986Newly Diagnosed, Advanced Ovarian Cancer, FIGO Stage III-IV, BRCA Mutation
AstraZeneca
Phase 3
450
Akashi-shi, Chūōku, Fukuoka, Hidaka-shi, Matsuyama, Niigata, Sapporo, Sunto-gun
2013-08-26
Active, closed
AstraZeneca
Phase 2
162
Chūōku, Fukuoka, Matsuyama, Morioka, Shinjuku-ku, Yamagata, Yonago-shi
2010-02-04
Rows per page Showing 1–19 of 19
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Japanese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 22 October 2026. https://priyalifescience.com/clinical-trials-japan/city/matsuyama

Query this register directly
GET /api/trials?country=in&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in Japan and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 2,493 studies in total at the last sync on 22 Oct 2026, 03:19 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 19 of those studies with a site in Matsuyama that also match the filters currently applied.

How many clinical trials are recruiting in Matsuyama?

7 of the 19 studies on this page are recruiting new participants as of the 22 Oct 2026, 03:19 UTC sync. A further 0 have not yet opened recruitment, 12 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Matsuyama), 19 studies
PhaseStudiesRecruitingShare
Phase 315578.9%
Phase 23115.8%
Phase 1/2115.3%

Most active sponsors

Lead sponsors with the most studies (Matsuyama)
Lead sponsorStudiesRecruiting
AstraZeneca197
→

Other trial registries in Japan

This register lists Japan studies from ClinicalTrials.gov. Many studies in Japan are registered only in a national registry. We do not copy those records; search them directly:

  • jRCT (Japan Registry of Clinical Trials) — run by the Ministry of Health, Labour and Welfare; trials under Japan's Clinical Trials Act and other clinical research
  • UMIN-CTR — run by the University of Tokyo Hospital's UMIN Center; many academic and investigator-led studies
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and China registers.